Novel Drug Reconstitution Systems, 2014 - 2024

News provided by

Research and Markets

10 Dec, 2014, 11:00 GMT

DUBLIN, Dec. 09, 2014 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/zpmxsw/novel_drug) has announced the addition of the "Novel Drug Reconstitution Systems, 2014 - 2024" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

In today's pharmaceutical market, many drugs are supplied in powdered formulation because of their lower shelf life in liquid formulation. The drugs are formulated into powdered form by various processes such as lyophilisation or spray drying; these drugs are then reformulated into liquid form by mixing with a suitable diluent at the time of administration.

The overall market of drug reconstitution systems is characterised by the presence of around 50 devices (both conventional and novel). The primary goal of these systems is to provide a hassle free reconstitution process in minimal number of steps. In addition, these systems also aim to provide an optimal protection from needlestick injuries to both the patients and healthcare providers.

Conventional drug reconstitution systems, including Vial Adaptors, Vial to Vial Systems, Direct Connection to Vial Systems and a few others, currently dominate the market. Some of these systems were developed nearly two decades ago and have gained a significant share of the market overtime.

In addition, the use of traditional hypodermic needles for reconstituting the drug using a diluent vial is still widespread, especially in the developing countries. However, with new needlestick injuries prevention laws being implemented, along with rising approvals for biologic drugs, novel reconstitution systems such as Dual Chamber Systems are expected to be more popular and preferred option. A number of these novel systems make the process as easy as the push of a button in a much more safer and accurate manner.

Though the market for such novel devices is currently at nascent stage, there are several devices available for investigational use. The technology used in novel systems is likely to play an important part in enhancing the safety, patient compliance and ease of use. When ready, these devices are likely to have a significant impact on the overall market landscape.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET OVERVIEW

5. DUAL CHAMBER SYSTEMS

6. OTHER NOVEL SYSTEMS

7. NEEDLE FREE SYSTEMS

8. CONVENTIONAL RECONSTITUTION SYSTEMS

9. MARKET FORECAST

10. APPROVED DRUGS AND VACCINES

11. COMPANY PROFILES

12. INDUSTRY PARTNERSHIPS AND TECHNOLOGICAL EVOLUTION

13. SWOT ANALYSIS

14. INTERVIEW TRANSCRIPTS

15. CONCLUSION

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES

Companies Mentioned:

  • Acambis
  • Adelphi Healthcare Packaging
  • Allergan
  • Amgen
  • Amylin
  • Arte Corporation
  • AstraZeneca
  • Auxilium Pharmaceuticals
  • B. Braun Medical
  • Baxter
  • Becton Dickinson
  • Biodel
  • Biogen Idec
  • Bioject
  • Bracco Diagnostics Inc
  • Bristol-Myers Squibb
  • CSL Behring
  • CareFusion
  • Cato Software Solutions
  • Cerexa
  • Codan
  • Crucell
  • Daikyo Seiko
  • Disetronic Group
  • Dongbao
  • Duoject
  • Durata Therapeutics
  • Elan Corporation (acquired by Perrigo)
  • Elcam medical
  • Eli Lilly
  • Ferring Pharmaceuticals
  • Flashmed Inc.
  • Flextronics
  • Fondaco PTE Ltd.
  • Future injection technologies
  • GTC BioTherapeutics
  • GenCell Biosystems
  • Genentech
  • Genzyme Corporation
  • Gilead
  • GlaxoSmithKline
  • Global Holdings
  • Globe Medical Tech.
  • Haemopharm
  • Hikma
  • ICU Medical
  • Incepta Pharmaceuticals
  • Infusion Solution Inc.
  • Infusive Technologies
  • Integrity Bio
  • Ipsen Biopharm Limited
  • Janssen Biotech
  • Labrys Biologics
  • Lundbeck
  • Lupin Ltd.
  • MJ Biopharm
  • Macopharma
  • MedImmune
  • Medimop Medical Projects Ltd.
  • Merck
  • Microdose
  • Millennium Pharmaceuticals
  • Mystic Pharmaceuticals
  • NPS Pharmaceuticals
  • Navidea Biopharmaceuticals Inc.
  • Novartis
  • NuPathe
  • Nycomed
  • Octapharma
  • Organon Teknika Corp LLC
  • Penjet corporation
  • Pfizer
  • Pharming Group
  • Pharmstandard
  • Polfa Tarchomin
  • Premier Inc.
  • ProJect Pharmaceutics
  • Progressive Medical Inc.
  • Publix Super Markets
  • Recon Therapeutics
  • Roche Holdings
  • SHL Medical
  • Safety Syringes
  • Sanofi
  • Sensile Medical
  • Shire Pharmaceuticals
  • Square Pharmaceuticals
  • Technoflex
  • Teva
  • Theratechnologies
  • Theravance
  • UCB
  • Unilife
  • Vetter Pharma
  • Watson Pharmaceuticals
  • Weibel CDS AG
  • West Pharma
  • Ypsomed
  • Yukon Medical
  • scPharmaceuticals

For more information visit http://www.researchandmarkets.com/research/zpmxsw/novel_drug

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com